Hosted on MSN1mon
FDA accepts Eisai/Biogen’s BLA for LEQEMBI in early AD treatment
The company states: “Eisai (ESAIY) and Biogen (BIIB) announced that the FDA ... LEQEMBI is indicated for the treatment of Alzheimer’s disease – AD – in patients with Mild Cognitive ...
Benzinga.com1mon
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. Also Read: Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown If ...